A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00700427
First received: June 16, 2008
Last updated: October 17, 2013
Last verified: October 2013
Results First Received: August 23, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: atomoxetine hydrochloride
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
The study consisted of 3 treatment periods: 12 weeks open-label, acute-treatment phase (Study Period 2), 12 weeks double-blind maintenance phase of Study Period 3 (Study Period 3A) and 25 weeks double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).

Reporting Groups
  Description
Atomoxetine (Study Period 2) 40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during open-label, acute-treatment phase (Study Period 2).
Atomoxetine (Study Period 3A) 80-100 mg/day for 12 weeks during double-blind maintenance phase of Study Period 3 (Study Period 3A)
Atomoxetine (Study Period 3B) 80-100 mg/day atomoxetine orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).
Placebo (Study Period 3B) Placebo orally, once daily or twice daily for 25 weeks during double-blind randomized withdrawal phase of Study Period 3 (Study Period 3B).

Participant Flow for 3 periods

Period 1:   Study Period 2
    Atomoxetine (Study Period 2)     Atomoxetine (Study Period 3A)     Atomoxetine (Study Period 3B)     Placebo (Study Period 3B)  
STARTED     2017     0     0     0  
Received at Least One Dose of Study Drug     2011     0     0     0  
COMPLETED     1006 [1]   0     0     0  
NOT COMPLETED     1011     0     0     0  
Adverse Event                 298                 0                 0                 0  
Protocol Violation                 173                 0                 0                 0  
Withdrawal by Subject                 164                 0                 0                 0  
Protocol Interim Criteria Not Met                 161                 0                 0                 0  
Lost to Follow-up                 108                 0                 0                 0  
Lack of Efficacy                 90                 0                 0                 0  
Physician Decision                 8                 0                 0                 0  
Clinical Relapse                 7                 0                 0                 0  
Entry Criteria Not Met                 2                 0                 0                 0  
[1] One participant was mistakenly recorded as completed. The reason for discontinuation is unknown.

Period 2:   Study Period 3A
    Atomoxetine (Study Period 2)     Atomoxetine (Study Period 3A)     Atomoxetine (Study Period 3B)     Placebo (Study Period 3B)  
STARTED     0     1005     0     0  
COMPLETED     0     524     0     0  
NOT COMPLETED     0     481     0     0  
Adverse Event                 0                 50                 0                 0  
Protocol Interim Criteria Not Met                 0                 162                 0                 0  
Withdrawal by Subject                 0                 81                 0                 0  
Protocol Violation                 0                 56                 0                 0  
Clinical Relapse                 0                 49                 0                 0  
Lost to Follow-up                 0                 41                 0                 0  
Lack of Efficacy                 0                 32                 0                 0  
Sponsor Decision                 0                 3                 0                 0  
Physician Decision                 0                 2                 0                 0  
Missing - Not Otherwise Defined                 0                 5                 0                 0  

Period 3:   Study Period 3B
    Atomoxetine (Study Period 2)     Atomoxetine (Study Period 3A)     Atomoxetine (Study Period 3B)     Placebo (Study Period 3B)  
STARTED     0     0     266     258  
COMPLETED     0     0     184     165  
NOT COMPLETED     0     0     82     93  
Adverse Event                 0                 0                 8                 5  
Withdrawal by Subject                 0                 0                 25                 34  
Protocol Violation                 0                 0                 23                 25  
Lost to Follow-up                 0                 0                 19                 9  
Lack of Efficacy                 0                 0                 3                 11  
Protocol Interim Criteria Not Met                 0                 0                 0                 5  
Clinical Relapse                 0                 0                 0                 3  
Missing                 0                 0                 1                 1  
Physician Decision                 0                 0                 2                 0  
Death                 0                 0                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All enrolled participants.

Reporting Groups
  Description
Atomoxetine (40-100 mg) 40-100 milligrams/day (mg/day) atomoxetine orally, once daily or twice daily for 12 weeks during open-label, acute-treatment period (Study Period 2).

Baseline Measures
    Atomoxetine (40-100 mg)  
Number of Participants  
[units: participants]
  2017  
Age  
[units: years]
Mean ± Standard Deviation
  33.15  ± 9.09  
Gender  
[units: participants]
 
Female     833  
Male     1184  
Race/Ethnicity, Customized  
[units: participants]
 
Caucasian     1765  
African     56  
Hispanic     159  
Native American     6  
East Asian     14  
West Asian     15  
Missing     2  
Region of Enrollment  
[units: participants]
 
Argentina     27  
Austria     109  
Belgium     137  
Canada     60  
Denmark     15  
Finland     52  
France     65  
Germany     434  
Italy     32  
Mexico     53  
Netherlands     71  
Portugal     3  
Puerto Rico     52  
Russian Federation     6  
Spain     153  
Sweden     112  
Switzerland     7  
United Kingdom     27  
United States     602  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period   [ Time Frame: Baseline (Week 24) up to Week 49 ]

2.  Secondary:   Number of Days Until Relapse   [ Time Frame: Baseline (Week 24) up to Week 49 ]

3.  Secondary:   Change From Baseline in the Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Quality of Life (AAQoL) Scale From Week 24 to Week 49   [ Time Frame: Baseline (Week 24), Week 49 ]

4.  Secondary:   Change From Baseline in Conner's Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (Observer Rated [CAARS-O:SV]) Total ADHD Symptom Score From Week 24 to Week 49   [ Time Frame: Baseline (Week 24), Week 49 ]

5.  Secondary:   Change From Baseline in Conner's Adult ADHD Rating Scale-Self Rated (CARRS-S:SV) Total ADHD Symptom Score From Week 24 to Week 49   [ Time Frame: Baseline (Week 24), Week 49 ]

6.  Secondary:   Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version: Self Report (BRIEF-A:Self Report) Global Executive Composite (GEC) Index Score From Week 24 to Week 49   [ Time Frame: Baseline (Week 24), Week 49 ]

7.  Secondary:   Change From Baseline in the Behavior Rating Inventory of Executive Function-Adult Version:Informant Report (BRIEF-A:Informant) Global Executive Composite (GEC) Index Score From Week 24 to Week 49   [ Time Frame: Baseline (Week 24), Week 49 ]

8.  Secondary:   Change From Baseline in European Quality of Life (EuroQoL) Questionnaire-5 Dimensions (EQ-5D) Index Score From Week 24 to Week 49   [ Time Frame: Baseline (Week 24), Week 49 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Chief Medical Officer
Organization: Eli Lilly and Company
phone: 800-545-5979


No publications provided


Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00700427     History of Changes
Other Study ID Numbers: 9655, B4Z-MC-LYDO
Study First Received: June 16, 2008
Results First Received: August 23, 2012
Last Updated: October 17, 2013
Health Authority: United States: Food and Drug Administration